PDF links
DENIS LABORATORY — RECENT REVIEWS
1. A new hypothesis that many inflammatory diseases, including cancer and Type 2 diabetes, have a common epigenetic foundation.
Denis (2010). Discovery Med 10(55): 489-499.
2. Major significance of the Brd2 hypomorphic phenotype for obesity and Type 2 diabetes.
Belkina & Denis (2010). Curr Opin Endocrinol Diabetes Obes 17(5): 472-477.
3. New mechanisms of transcriptional co-activation in adipogenesis and energy metabolism.
Denis, Nikolajczyk & Schnitzler (2010). FEBS Lett 584(15): 3260-3268.
DENIS LABORATORY — KEY PUBLICATIONS
1. Whole-body reduction of Brd2 levels in mice leads to the very surprising result that mice become extremely obese, yet are preserved from insulin resistance and Type 2 diabetes.
Wang F., H. Liu, W. P. Blanton, A. Belkina, N. K. LeBrasseur and G. V. Denis (2010). Brd2 disruption in mice causes severe obesity without Type 2 diabetes. Biochem. J. 425: 71 – 83. PMID: 19883376
Click here to view PDF.
Please note: This is a PDF. To download the latest version, go to: www.adobe.com.
2. Bromodomain protein Brd2-driven B cell malignancy in a mouse model.
Greenwald R., J. R. Tumang, A. Sinha, N. Currier, R. D. Cardiff, T. L. Rothstein, D. V. Faller and G. V. Denis (2004). Eμ-BRD2 transgenic mice develop B cell lymphoma and leukemia. Blood 103: 1475 – 1484. PMID: 14563639
3. Bromodomain analysis of cyclin A transcription.
Sinha, A., D. V. Faller and G. V. Denis (2005). Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A. Biochem. J. 387: 257 – 269.
PMID: 15548137; PMC: 1134954
Click here to view PDF.
4. MALDI and LC-MS/MS identification of Brd2 multiprotein complexes.
Denis, G. V., M. E. McComb, D. V. Faller, A. Sinha, P. B. Romesser and C. E. Costello (2006). Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. J. Proteome Res. 5: 502 – 511. PMID: 16512664; PMC: 2823066
Click here to view PDF.
5. Genome-wide transcriptional and proteomic profiling reveal a malignancy signature of diffuse large B cell lymphoma.
Lenburg, M., A. Sinha, D. V. Faller and G. V. Denis (2007). Tumor-specific and proliferation-specific gene expression typifies murine transgenic B cell lymphomagenesis. J. Biol. Chem. 282: 4803 – 4811. PMID: 17166848; PMC: 2819333
Click here to view PDF.
Romesser, P. B., D. H. Perlman, D. V. Faller, C. E. Costello, M. E. McComb and G. V. Denis (2009). Development of a malignancy-associated proteomic signature for diffuse large B cell lymphoma. Am. J. Pathol. 175: 25–35. PMID: 19498000; PMC: 2708791
6. Therapeutics for leukemia and lymphoma.
Denis, G. V. (2007). Imatinib mesylate (Gleevec) and the emergence of chemotherapeutic drug-resistant mutations. In H. L. Kaufman, S. Wadler and K. H. Antman, Eds., Cancer Drug Discovery and Development; Specific Drugs for Molecular Targeting in Oncology,, Part IV, Chapter 22. Humana Press; Totowa, NJ. In press.
Click here to view PDF.
Longe, H., P. B. Romesser, A. Rankin, D. V. Faller, M. S. Eller, B. A. Gilchrest and G. V. Denis (2009). Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: Mechanism and therapeutic potential. Int. J. Cancer. 124:473–482. PMID: 19003960
